Target therapy
DESTINY-Breast02 trial: Trastuzumab deruxtecan after failure on TDM-1, An Update
In the phase 3 DESTINY-Breast02 trial, #Trastuzumab deruxtecan (T-DXd) improved the PFS and OS in patients with HER2-positive metastatic breast...
GOG-0218 trial - KELIM scores
In a retrospective analysis of the GOG-0218 trial, a modelled CA-125 ELIMination rate constant K (#KELIM) could identify patients who...
RIGHT Choice trial - Ribociclib + Endocrine therapy PFS
-TN23-BC-.png)
The combination of ribociclib and endocrine therapy improved PFS in the first-line setting for premenopausal patients with aggressive ER-positive, HER2-negative...
SWOG S1207 trial - 1year adjuvant Everolimus to adjuvant Endocrine Therapy
In the phase 3 SWOG S1207 trial, the addition of 1 year of adjuvant Everolimus to adjuvant endocrine therapy failed...
CAPItello-291 trial - Capivasertib, oral AKT inhibitor, + Fulvestrant
In the phase 3 CAPItello-291 trial, presented at the SABCS, the addition of #capivasertib, an oral AKT inhibitor, to fulvestrant...
Dabrafenib + Trametinib FDA approval for treatment of adult and pediatric patients (aged 6 and older) with unresectable or metastatic solid tumors with BRAF V600E mutation
On June 22, 2022, the #FDA granted an accelerated approval to #dabrafenib in combination with #trametinib for treatment of adult...
SOPHIA trial
#Margetuximab failed to improve OS in patients with pretreated HER2- positive metastatic #breast_cancer in the final overall survival analysis of...
ENGOT/GCIG trial
In the prospective, randomized ENGOT/GCIG study by AGO s, GINECO, NSGO study groups, standard duration of #bevacizumab (15 months) treatment...
COSMIC-313 trial
In COSMIC-313 trial presented by Dr. Toni Choueiri, #cabozantinib (C) in combination with #nivolumab (N) and #ipilimumab (I) improved PFS...
RESONATE-2 trial
In the updated analysis of phase III RESONATE-2 trial, treatment with BTK inhibitor (#ibrutinib) for at least 5 years showed...
TRIPLETE trial
In phase III TRIPLETE Study by GONO group, the intensification of the upfront chemotherapy backbone in combination with #panitumumab did...
COSMIC-312 trial
In COSMIC-312 trial, first line #Cabozantinib plus #atezolizumab improved PFS versus #sorafenib for patients with advanced HCC. In this phase...
POSEIDON trial
The results of the exploratory analysis from POSEIDON trial were presented by Dr. Melissa Johnson. In this phase III trial,...
DESTINY-Lung02 trial
In DESTINY-Lung02 trial Presented by Dr. Koichi Goto, Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg and 6.4 mg/kg demonstrated clinically meaningful activity...
CodeBreak 200 trial
In phase III CodeBreak 200 trial presented by Dr. Melissa Johnson, oral #sotorasib demonstrated superior PFS and ORR compared to...
Trastuzumab deruxtecan FDA approval in metastatic NSCLC
On August 11, 2022, the FDA approved #fam-trastuzumab deruxtecan-nxki (5.4 mg/kg IV every 3 weeks) for adult patients with have...
KEYLYNK-010 trial
In the randomized KEYLYNK-010 study presented by Dr. Evan Yu, #Pembrolizumab + #olaparib (P+O) failed to improve rPFS or OS...
.png)